Spyre Therapeutics, Inc. (SYRE) – What Are Analysts Saying About This Stock?

by · The Cerbat Gem

Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the seventeen analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $110.40.

A number of equities analysts recently issued reports on the company. Mizuho lifted their target price on Spyre Therapeutics from $84.00 to $120.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Deutsche Bank Aktiengesellschaft dropped their price target on Spyre Therapeutics from $135.00 to $127.00 and set a “buy” rating on the stock in a research note on Wednesday, August 26th. BTIG Research restated a “buy” rating and set a $121.00 price objective on shares of Spyre Therapeutics in a report on Monday, October 19th. UBS Group assumed coverage on shares of Spyre Therapeutics in a research note on Sunday, October 11th. They set a “buy” rating and a $120.00 price objective for the company. Finally, Wall Street Zen cut shares of Spyre Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday.

View Our Latest Stock Analysis on SYRE

Insiders Place Their Bets

In other Spyre Therapeutics news, insider Heidy King-Jones sold 28,933 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $91.03, for a total value of $2,633,770.99. Following the completion of the sale, the insider owned 2,845 shares in the company, valued at $258,980.35. This represents a 91.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Cameron Turtle sold 15,000 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $87.29, for a total value of $1,309,350.00. Following the sale, the chief executive officer owned 552,540 shares of the company’s stock, valued at approximately $48,231,216.60. This represents a 2.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 161,064 shares of company stock valued at $14,753,768 over the last ninety days. Corporate insiders own 15.69% of the company’s stock.

Institutional Trading of Spyre Therapeutics

A number of institutional investors have recently added to or reduced their stakes in SYRE. GAMMA Investing LLC lifted its stake in shares of Spyre Therapeutics by 26.8% in the 2nd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $59,000 after purchasing an additional 140 shares during the last quarter. AlphaCentric Advisors LLC boosted its position in Spyre Therapeutics by 4.3% during the third quarter. AlphaCentric Advisors LLC now owns 6,956 shares of the company’s stock worth $619,000 after purchasing an additional 286 shares during the period. Integrated Wealth Concepts LLC bought a new stake in Spyre Therapeutics during the second quarter worth approximately $31,000. Summit Securities Group LLC bought a new stake in Spyre Therapeutics during the first quarter worth approximately $28,000. Finally, Nisa Investment Advisors LLC grew its holdings in Spyre Therapeutics by 24.3% during the third quarter. Nisa Investment Advisors LLC now owns 2,918 shares of the company’s stock valued at $260,000 after purchasing an additional 571 shares during the last quarter. 80.39% of the stock is currently owned by institutional investors and hedge funds.

Spyre Therapeutics Price Performance

SYRE stock opened at $99.27 on Wednesday. The firm has a market cap of $10.12 billion, a PE ratio of -50.91 and a beta of 3.24. Spyre Therapeutics has a 12 month low of $21.15 and a 12 month high of $110.18. The firm has a 50 day simple moving average of $89.69 and a 200 day simple moving average of $73.50.

Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by ($0.15). As a group, sell-side analysts expect that Spyre Therapeutics will post -2.71 earnings per share for the current year.

About Spyre Therapeutics

(Get Free Report)

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation treatments for inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. The company’s approach is centered on engineered antibody therapies designed to provide durable disease control, convenient dosing and improved treatment characteristics.

Spyre’s investigational pipeline includes antibody programs directed at important inflammatory pathways, including interleukin-23 (IL-23) and TL1A.

Further Reading